List view / Grid view
17 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A test of contrast-enhanced subharmonic imaging has shown promise in detecting prostate cancers that were not identified by MRI...
6 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately...
3 April 2018 | By European Pharmaceutical Review
By taking Zytiga with a low-fat meal could decrease the daily dose and prevent digestive issues...
21 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers are testing the use of pulsed sound waves to direct and focus cancer drug therapies...
6 March 2018 | By European Pharmaceutical Review
An Italian study demonstrates that copper accumulation in tumours can detect prostate cancer recurrence early in patients with biochemical relapse...
16 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have shed new light on the genetic mechanisms that promote metastasis and implicated the typical Western high-fat diet as a key environmental factor...
5 December 2017 | By European Pharmaceutical Review
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
22 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
16 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A Norwegian study shows that NTZ contains a substance that can kill prostate and colon cancer...
12 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
19 January 2017 | By Niamh Marriott, Digital Editor
Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…
1 July 2016 | By Victoria White, Digital Content Producer
NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases...
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
3 June 2016 | By Victoria White, Digital Content Producer
The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer...
Send this to a friend
Follow: